INCRESYNC

This brand name is authorized in Austria, Croatia, Estonia, Finland, Ireland, Italy, Lithuania, Poland, Spain.

Active ingredients

The drug INCRESYNC contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII JHC049LO86 - ALOGLIPTIN
 

Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.

 
Read more about Alogliptin
2
UNII X4OV71U42S - PIOGLITAZONE
 

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

 
Read more about Pioglitazone

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 INCRESYNC Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
A10BD09 Pioglitazone and alogliptin A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1626667, 1626678, 1626689, 1626690, 1626702, 1626713, 1626724, 1626735, 1626746, 1626757, 1626768, 1626779, 1626780, 1626791, 1626803, 1626814, 1626825, 1626836, 1626847, 1626858, 1626869, 1626870, 1626881, 1626892, 1626904, 1626915, 1626926, 1626937, 1626948, 1626959, 1626960, 1626971, 1626982, 1626993, 1627006, 1627017
ES Centro de información online de medicamentos de la AEMPS 113842003, 113842021
FI Lääkealan turvallisuus- ja kehittämiskeskus 134709
IT Agenzia del Farmaco 043030016, 043030028, 043030030, 043030042, 043030055, 043030067, 043030079, 043030081, 043030093, 043030105, 043030117, 043030129, 043030131, 043030143, 043030156, 043030168, 043030170, 043030182, 043030194, 043030206, 043030218, 043030220, 043030232, 043030244, 043030257, 043030269, 043030271, 043030283, 043030295, 043030307, 043030319, 043030321, 043030333, 043030345, 043030358, 043030360
LT Valstybinė vaistų kontrolės tarnyba 1071372, 1071373, 1071374, 1071375, 1071376, 1071377, 1071378, 1071379, 1071380, 1071381, 1071382, 1071383, 1071384, 1071385, 1071386, 1071387, 1071388, 1071389, 1071390, 1071391, 1071392, 1071393, 1071394, 1071395, 1071396, 1071397, 1071398, 1071399, 1071400, 1071401, 1071402, 1071403, 1071404, 1071405, 1071406, 1071407
PL Rejestru Produktów Leczniczych 100310938, 100310944, 100310950, 100310973

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.